drugset / Trial / NCT05368207
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient
NaSingle-groupOpen-labelTreatment
Summary
This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Timeline
- Start
- 2021-12-06
- Primary completion
- 2025-10-16
- Completion
- 2025-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |